Uncategorized Archives - Page 920 of 956

FridayDec 02, 2016 3:44 pm

Singlepoint, Inc. (SING) CEO Discusses Influx of Calls from Cannabis Dispensaries on MoneyTV with Donald Baillargeon

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future. To view this week’s program, visit www.MoneyTV.net In the interview, Greg Lambrecht, chief executive officer of Singlepoint, offered prospective investors an update on the progress of the company’s SingleSeed subsidiary, which it awakened from a quiet period in early November in an effort…

FridayDec 02, 2016 1:09 pm

Momenta Pharmaceuticals, Inc. (MNTA) is “One to Watch”

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) is a biotechnology company focused on the development of generic versions of complex drugs. The company is in the business of discovering and developing new therapies for oncology and autoimmune indications. Currently, the company has four products still in the development stage (hsIVIg, M230, five biosimilar programs, and M834), two in clinical stage one trials (M281 and M923), one in the process of being BLA and NDA accepted (40 mg/ml COPAXONE®), and two already being sold at market (LOVENOX® and 20 mg/ml COPAXONE®). Most recently, the company announced positive top-line phase III results for M923,…

FridayDec 02, 2016 12:34 pm

SQI Diagnostics, Inc. (SQIDF) Changing How Diagnostics Testing Works

Diagnostic labs and drug developers are in a constant search for cheaper, better, faster test results, and SQI Diagnostics (OTCQX: SQIDF) is focused on meeting this demand. The company reduces the timeline for urgently-needed test results and the amount of labor needed, all without forfeiting quality. SQI Diagnostics is a life sciences and diagnostics company that supports better health care through the development and marketing of technologies and products that propel faster and more accurate advanced multiplexing diagnostics. From SQI’s base in Toronto, a team of expert scientists develops custom research and diagnostic assays that are multiplexed to consolidate and…

FridayDec 02, 2016 12:05 pm

Fortress Biotech, Inc. (FBIO) set to Profit from Profuse Product Portfolio

Fortress Biotech, Inc. (NASDAQ: FBIO) is not putting all its eggs in one basket. This is a biopharmaceutical company with multiple revenue streams and a profuse product portfolio so diversified that Harry Markowitz, the father of modern portfolio theory, might tip his hat to the way the company has sought to mitigate developmental risks. Fortress’ diverse product pipeline also gives it multiple shots at hitting its financial goals, increased by the symbiotic relationship between development areas. The research platforms are structured so that success in one area is likely to add impetus to another. Fortress is parent to a group…

FridayDec 02, 2016 11:07 am

Agora Holdings, Inc. (AGHI) Aims to Streamline Personal Branding with FRAME

Before the opening bell, Agora Holdings, Inc. (OTC: AGHI) issued an update on its FRAME social media management technology, providing some additional insight into how the platform can be used to streamline personal branding efforts for both individuals and businesses. The news release highlights the importance of establishing and maintaining a presence on social media in order to accomplish a variety of goals. Whether created to stay connected, meet new people, get the word out about a new business or run for public office, maintaining an effective online presence is made easier with Agora’s recently launched FRAME technology. “The boundary…

FridayDec 02, 2016 9:11 am

Akebia Therapeutics (AKBA) ‘Buy’ Rating Reiterated with Higher Stock Price Target of $18

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharma company that focuses on the development of innovative treatments for chronic kidney disease-related anemia, is maintaining its ‘Buy’ rating, with a recommended stock price target of $18 compared to the current $8.90, according to an Aegis Capital Corp. report (http://nnw.fm/F4ezY) released on November 15. The rating and suggested stock price were based on discounted cash flow analysis and the estimated 2016-2022 EBITDA, with a discount rate of eight percent, the report said. The analysis also assumed a 60 percent probability of clinical success for Akebia’s lead product candidate Vadadustat, currently in development as…

ThursdayDec 01, 2016 4:46 pm

National Waste Management Holdings, Inc. (NWMH) Plans Further Growth with Targeted Acquisitions

In its latest quarterly report (10-Q), National Waste Management Holdings (OTC: NWMH), a solid waste management company headquartered in central Florida, demonstrated impressive growth. The company is currently running at full speed to achieve its stated objective of becoming a leading national solid waste company through organic growth and acquisitions. Revenues for the third quarter ended September 2016 were stellar at $1.8 million, rising by 269 percent over the third quarter 2015 figure of $0.5 million. Revenues for the nine-month period ended September 2016 were $4.9 million, representing similar growth over 2015 same period revenues of $1.3 million. Now with…

ThursdayDec 01, 2016 4:24 pm

Citius Pharmaceuticals, Inc. (CTXR) is “One to Watch”

Citius Pharmaceuticals, Inc. (OTCQB: CTXR), a specialty biopharmaceutical company that develops and commercializes therapeutics products, has been a topic of conversation among analysts since the initiation of its phase III clinical trial of Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters and treat bloodstream infections that stem from catheters. This phase III randomized, double-blind, multi-center study involves 700 patients and has a primary goal of measuring whether or not the majority of subjects have overall success maintaining the treated central venous catheters during the cure test in week eight. The company will also be testing the…

ThursdayDec 01, 2016 3:10 pm

Agora Holdings, Inc. (AGHI) – Framing the Narrative for Social Brands

The human imagination is capable of incredibly brilliant creations, including the technological innovations that Agora Holdings, Inc. (OTC: AGHI) is developing to create tools that can help people and companies save time and improve performance, all while publishing more content. Agora Holdings, together with subsidiary Geegle Media and its affiliates, is a global family entertainment and media enterprise with five business segments: consumer products, interactive media, media networks, studio entertainment and television. Agora Holdings engages in the development of bespoke software applications from its base in North York, Canada. Agora and its subsidiary Geegle Media are committed to delivering media…

ThursdayDec 01, 2016 2:06 pm

Zogenix, Inc. (ZGNX) Develops Orphan Drug for Dravet Syndrome Epilepsy

Zogenix, Inc (NASDAQ: ZGNX) is a clinical stage pharmaceutical company committed to the development and commercialization of therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases. The company’s lead product candidate, ZX008, is currently being evaluated for the treatment of one such disease – Dravet Syndrome. Despite the name, orphan diseases affect adults as well. The soubriquet ‘orphan disease’ arose because pharmaceutical companies showed no interest in ‘adopting’ them due to their comparatively small market size. However, the Orphan Drug Act (ODA) of 1983 created financial incentives for drug and biologics manufacturers…